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 ABSTRACT 
Introduction: One of the most important and long recognised characteristics of tumour 
cells is their dysregulated cellular energetics with anaerobic driven glucose uptake. In 
patients with cancer the prognostic value of the systemic inflammatory response has been 
well established and the recent combination of PET and CT scanning combines the 
assessment of tumour physiological activity with detailed anatomical localisation.  The 
aim of this study was to carry out a systematic review of the assessment of the relationship 
between both the tumour and host inflammatory responses using PETCT.  
Methods: An extensive literature review using targeted subject headings was carried out 
in the US National Library of Medicine, the Excerpta Medica database and Cochrane 
Database of Systematic Reviews until the 31st March 2018.  On completion of the online 
search, the title and abstracts of each identified study was examined for relevance. Studies 
with duplicate datasets, not available in English and that did not have full text availability 
were excluded. Full texts of relevant articles were obtained and were then examined to 
identify any further relevant articles.  
Results: Twelve studies containing 2,588 patients were included in the final analysis.  All 
of the included studies used the 18FDG tracer in PETCT imaging and had biochemical 
assessment of the systemic inflammatory response. The majority of studies showed a 
direct relationship between the tumour and bone marrow glucose uptake and host systemic 
inflammatory responses as measured by C-Reactive Protein (CRP) (n=2), albumin (n=2), 
White Cell Count (WCC) (n=3), neutrophils (n=2) and platelets (n=2). The majority of the 
studies (n=8) also showed a direct relationship between tumour and bone marrow glucose 
uptake and poor outcomes.   
Conclusion:  This review suggests a direct relationship between the tumour and bone 
marrow glucose uptake and host systemic inflammation.  This may suggest new 
 approaches for more optimal therapeutic targeting and monitoring strategies in patients 
with cancer. 
 
Keywords: Systemic inflammation, Cancer, Glasgow Prognostic Score, Neutrophil 
Lymphocyte Ratio, Platelet Lymphocyte Ratio, Lymphocyte Monocyte Ratio, Positron 





Cancer remains one of the leading causes of mortality worldwide and is responsible 
for approximately  8.8 million deaths per year(1). Overall, it has been estimated that one in 
three people will develop cancer in their lifetime, and one in four will die from it (2,3).  
Indeed, in the UK alone it is estimated that 150,000 people die of cancer each year (1,3). Four 
cancers- lung, colorectal, breast and prostate account for approximately half of all new cases 
and deaths (2).  
 At a cellular level there are several traits of cancer that define its malignancy. These 
include genome instability, limitless replicative potential, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, the ability to evade apoptosis, sustained angiogenesis, 
tissue invasion and metastasis, abnormal metabolic pathways, inflammation and evasion of 
the immune system (4,5). All these hallmarks create what is known as the tumour 
microenvironment (TME, (4-6)). The TME is composed of heterogeneous cell populations 
including tumour cells, immune cells, fibroblasts, adipocytes, blood vessels and 
the extracellular matrix. Therefore, there are interactions between malignant and non-
transformed cells via a host of signalling molecules) (7). The tumour and its environment are 
constantly interacting and this is an integral part of the tumour physiology, structure and 
function. The relationship between the tumour and its environment is essential to promote 
tumour cell growth and the development of metastasis (8).  
An important and long recognised characteristic of tumour cells is the dysregulated 
cellular energetics that results in the increased uptake of glucose(9). Warburg observed that 
tumour cells predominately produced adenosine 5′-triphosphate (ATP) via a high rate of 
glycolysis and consumption of glucose via the conversion of glucose to lactic acid.  He 
recognised that this was inefficient for the tumour cell to produce ATP when compared to 
normal oxidative phosphorylation (9,10). Moreover, due to this anaerobic glycolysis and 
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lactic acid formation the TME would become acidic allowing for the de-differentiation of 
normal and malignant cells (11).   Warburg hypothesised that this metabolic defect was the 
basis of tumour formation.  In recent years it has been concluded that this metabolic defect is 
the result of genetic damage (39). Nevertheless, the impact of such dysregulated energetics of 
the tumour cell remains of considerable interest. 
The TME is likely to have a direct impact on the innate immune response and 
activation of the systemic inflammatory response (SIR). This can be evidenced by increases 
in the circulating acute phase proteins such as C-Reactive Protein (CRP) and albumin and 
innate immune cells such as neutrophils and monocytes (12).  These immune cells are also 
metabolically active requiring large amounts of glucose.  
The prognostic value of the C-reactive protein, albumin and neutrophil counts in 
cancer has been well established in observational studies (13,14).   In the last 15 years there 
has been a movement towards the use of combined prognostic scores such as the GPS/mGPS 
(C-reactive protein and albumin) and ratios such as the NLR (neutrophils and lymphocytes) 
to standardise and maximise prognostic value (15,16).  
Therefore, it is of interest that imaging studies of the tumour have become an 
important element in the evaluation of detecting, staging and management of patients with 
cancer (17). Positron Emission Tomography (PET) is an established nuclear imaging 
technique based on the uptake of glucose that can examine the metabolism of tumours. 
However, PET provides relatively poor anatomical information whereas CT is commonly 
used in the initial diagnosis and staging of cancers.  
The recent routine clinical combination of PET and CT gives anatomic information 
with associated assessment of tumour physiological activity (18).  This provides better 
identification of metabolically active lesions improving the diagnostic accuracy and 
localisation of both the primary and metastatic lesions. In the oncological setting the tracer 
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18F-2-fluoro-2-deoxy-D-glucose (18FDG) is commonly used due to its longer half-life which 
aids in transportation and clinical application (19). However, a disadvantage of this tracer is 
that it is not tumour cell specific, and can accumulate where there are metabolically active 
cells such as immune cells.  For example, it is recognised to accumulate in bone marrow, 
presumably due to formation of metabolically active immune cells. This additional variability 
that can occur with uptake parameters such as the SUV (which depends on appropriate 
calibration and reconstruction methods with inter-site variability, and dependence on lesion 
or organ segmentation) has resulted in normalising uptake to other metabolically active 
tissues. Interestingly, an elevated bone marrow to liver ratio has been reported to have 
prognostic value in a variety of common solid tumours and an increased cytokine load due to 
malignancy (20).  
Based on the above, it is hypothesised that glucose metabolism in both tumour and 
host inflammatory responses are related. This present review is timely given the rapidly 
expanding role of immune therapies (e.g. immune checkpoint inhibition and adoptive T-cell 
therapy) to treat patients with metastatic cancers. Therefore, the aim of this study was to carry 
out a systematic review of the relationship between tumour and host inflammatory glucose 
metabolism using PETCT. A better understanding of these processes would be useful to 







This systematic review of published literature was undertaken according to a pre-
defined protocol described in the PRISMA-P statement. The primary outcome of interest of 
this systematic review was the relationship between tumour and host inflammatory glucose 
metabolism specifically using PETCT imaging in patients with cancer.  The secondary 
outcome of interest of this systematic review was the association between tumour and host 
inflammatory glucose metabolism as measured by PETCT imaging and survival in patients 
with cancer.  
Studies were identified via a literature search of the electronic databases the US 
National Library of Medicine, the Excerpta Medica database and the Cochrane Database of 
Systematic Reviews between 1984 and 2018 using the following keywords:  cancer, 
malignancy, metastasis, inflammation, glucose, positron, CT and PETCT (last search update 
on 31st March 2018). 
To be eligible for inclusion, studies had to meet the following criteria.  (a) Patients 
with cancer (b) PETCT analysis the imaging modality used (c) Tumour (T) and/or bone 
marrow (BM) activity measured by either SUVmax, SUVmean or the bone marrow to liver 
ratio (BLR: mean BMSUV to mean Liver SUV ratio) (d) markers of the systemic 
inflammatory response in the form of acute phase proteins (CRP and albumin) or components 
of the differential blood cell counts (neutrophils, leukocytes, monocytes and platelets) and 
their composite scores such as the modified Glasgow Prognostic Scores (mGPS), Platelet 
Lymphocyte Ratio (PLR) and NLR. Exclusion criteria included (a) studies not carried out in 
patients with cancer (b) studies not using PETCT as the main imaging modality (c) studies 
not assessing tumour and bone marrow activity and (d) studies not including measurement of 
the SIR.  
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 On completion of the online search, the title and abstract of each identified study was 
examined for relevance. Studies not in cancer patients, studies not available in English and 
those published in abstract form only were excluded. Where there were multiple publications 
from the same cohort the most recent paper was included.  Full texts were obtained for all 
studies deemed potentially relevant. Once further exclusions outlined above were carried out, 
the bibliographies of all included articles were subsequently hand searched to identify any 
additional studies. Due to the small number of studies and the heterogeneity of tumour type 
and tumour/bone marrow activity assessment, meta-analysis was not carried out.  
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RESULTS:  
Study Selection Process  
The study selection process is summarised in Figure 1. Initial search strategy 
identified 207 articles whose titles and abstracts were reviewed. Articles were excluded if 
they had not been carried out in humans (n=64), no full texts were available (n=12), those 
that were a systematic review/meta-analysis (n=32) and those not published in English (n=6). 
This led to a review of the full text of 93 articles. A further 83 articles were excluded as there 
was no direct comparison between the SIR and PET-CT output. The remaining 10 articles 
had their bibliographies reviewed in a systematic manner.  This identified a further 2 articles 
to be included in the final analysis leading to final figure of 12 articles considered in the 
present systematic review (20-31).   
 
Overall Analysis 
The eleven included studies contained a total of 2,468 patients with the number of 
patients included in individual studies varying from 32 to 1,034 (Supplementary File). There 
was a wide variety in cancer anatomical locations including lung (n=4), oral (n=3), colorectal 
(n=2), gastric (n=1), head and neck (n=1) and multiple anatomical locations (n=1). 
Geographically studies were from Korea (n=5), China (n=2), Belgium (n=1), Taiwan (n=1), 
Canada (n-1), Japan (n=1) and the UK (n=1).   
 
The majority of studies showed a direct relationship between the host systemic 
inflammatory response and the indices of FDG accumulation as measured by BLR (n=5), 
BMSUVmax (n=4), TSUVmax (n=4), BMSUVmean (n=2), NSUVmax (n=2), SUVpeak 
(n=1), MRV (n=1) and TLG (n=1). In addition, the majority of studies showed a direct 
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relationship between survival and indices of FDG accumulation BLR (n=3), TSUVmax 
(n=2), BMSUVmean (n=2), BMSUVmax (n=1), NSUVmax (n=1) and TLG (n=1).  
 
 
All studies used the radioisotope 18F-FDG. There was some variation in the type of 
scanners used with the most common scanners being Siemens (n=5) and General Electric 
(n=4). In all studies patients were required to fast for minimum of 4-6 hours prior to the PET-
CT study protocol being initiated and fasting blood glucose levels were measured prior to the 
administration of 18F-FDG. The majority of studies had a blood glucose threshold level of < 
150.0 mg/dL for the injection of the radioisotope. There was some variation in the activity of 
18F-FDG administered, however all studies used weight based protocols with administered 
activities ranging between 230-555 MBq. PET acquisition in the majority of studies was from 
base of skull to proximal thigh, using 6 – 8 bed positions, acquired 60 minutes post FDG 
administration. All reconstructions involved CT attenuation correction and iterative 
reconstruction algorithms specific to the camera manufacturer’s software. Regions of interest 
(ROI) were either drawn freehand, using a minimum SUV cut off or by using isocontour 
software. The SUV parameters measured varied slightly although in general the maximum 
and mean SUV values were measured for the primary tumour (TSUVmax, TSUVmean), 
nodal disease (NSUVmax, NSUVmean) and bone marrow (BMSUVmax, BMSUVmean). 
The bone marrow to liver ratio (BLR) was defined using SUVmean measurements in the 
bone marrow, obtained mainly from vertebral bodies, and SUVmean from an ROI in the right 
lobe of liver.  
 
The majority of studies focused on patients with stage I-III disease who were treated 
with surgical resection with or without adjuvant chemoradiotherapy (n=8). In those studies 
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where surgery was not the mainstay of treatment only one study had a majority of metastatic 
disease (79.2%) (24). Two studies were in Ear Nose and Throat (ENT) cancers with the 
treatment of choice being concurrent chemoradiotherapy and definitive radiotherapy (24,26). 
One study was in patients with advanced Non Small Cell Lung Cancer (NSCLC) not 
amenable to surgical resection and one study was in multiple cancer types again not amenable 
to surgical resection (20,28). 
 
The majority of studies use singular markers of the systemic inflammatory response 
including the WCC (n=9), CRP (n=7), haemoglobin (n=4), albumin (n=3), neutrophils (n=2), 
platelets (n=2), lymphocytes (n=1) and monocytes (n=1). In addition composite ratios and 
scores were used in several studies including the NLR (n=7), PLR (n=5) and mGPS (n=1). 
Multiple markers of the systemic inflammatory response were used however there was 
considerable heterogeneity in the specific markers used.  
 
Therefore, a meta-analysis could not be meaningfully carried out due to the 
heterogeneity of tumour stage, tumour type and markers of the SIR.  
 
Relationship Between Tumour Glucose Metabolism using TSUVmax/mean, 
BMSUVmax/mean and BLR and Host Inflammatory Responses  
 
As can be seen in the supplementary file the majority of studies would appear to be 
significantly association between activation of the SIR and increased tumour, bone marrow 
and nodal uptake in PET-CT. In particular, the largest study (n=1034) included in this review 
reported such a relationship (25). 
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Jeong and colleagues compared the prognostic values of circulating blood cell-based 
parameters and tumour FDG uptake in patients with stage I NSCLC(25). In total 1034 
patients were included in this study. They were all newly diagnosed with NSCLC and 
underwent PET-CT scanning as part of their preoperative workup prior to undergoing 
surgical resection (25).  Biochemical and haematological measurements in the form of WCC, 
neutrophil, lymphocyte and platelet counts were taken(25). These were then used to calculate 
the composite ratios NLR and PLR. PET-CT scan analysis focused on tumour FDG uptake 
(25).  
 
The median age of the included patients was 61.6 years and 58.9% were male with 
50.6% having never smoked(25). The majority of patients had adenocarcinomas (76.7%) and 
were treated by lobectomy (87.1%) (25).  There were 144 recurrences and the median follow 
up was 29.5 months (25). Patients with a high TSUVmax had significantly higher WCC 
(p<0.001), neutrophil (p<0.001) and lymphocyte counts (p=0.002), and a greater NLR 
(p=0.016) (25). On univariate Cox regression analysis, WCC (p=0.028), TSUVmax 
(p<0.001), age (p<0.001), gender (p=0.003), smoking (p=0.002), cell type (p=0.001), and 
TNM stage (p<0.001) were significantly associated with disease specific survival (25). On 
multivariate analysis, TSUVmax (HR: 2.22 95% CI, 1.52–3.25; p<0.001), tumour stage (HR: 
2.11 95% CI, 1.47–3.01; p<0.001), and old age (HR:1.03 95% CI, 1.01–1.05; p=0.002)  




The results of the present systematic review showed that, in the majority of studies, 
there was a direct relationship between the tumour and bone marrow glucose uptake and host 
systemic inflammatory responses in patients with common solid tumours.    
Both tumour and nodal glucose uptake and bone marrow glucose uptake were associated with 
poor outcome in these patients. Although bone marrow FDG accumulation may mainly 
reflect inflammatory responses, tumour and nodal FDG accumulation reflect the malignant 
grade of the tumour cells in addition to the inflammatory responses. Therefore, it may be that 
the nature of their associations with survival will be different.    
Taken together the present review provides new insight into the interaction between 
tumour and host.  This may suggest new approaches to more optimal therapeutic targeting 
and monitoring strategies for patients with cancer. 
 The basis of the relationship between tumour glucose uptake and markers of the 
systemic inflammatory response is not clear.  The importance of the tumour 
microenvironment is increasingly appreciated.  In addition to the tumour cells themselves 
stromal cells and inflammatory cells are now recognised to play a role in growth and 
progression of cancer. The predominant cells in the tumour stroma are the cancer-associated 
fibroblasts (CAFs) that have been shown to promote tumour progression and invasion 
through the production of growth factors, cytokines and metabolites and stimulate blood 
vessel formation (32). Such stromal cell activity is intimately linked to inflammatory cell 
activity and macrophages contribute to tumour progression and spread by the promotion of 
genetic instability, protection and nurturing of cancer stem cells, promotion of metastatic 
spread and the downregulation of the protective T-cell driven adaptive immune response (33-
35).  In turn, such macrophage activity appears to be dependent on the tumour stage, tissue 
involvement and microbiota (33). The macrophage influence on tumour activity can be pro-
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inflammatory and tumour growth promoting via the classical M1 pathway commonly 
upregulated by the inflammatory cytokines TNF-α and IL-6 (36). As well as anti-
inflammatory and tumour growth reducing via the alternative M2 pathway commonly 
unpregulated by the anti-inflammatory cytokines IL-4 and IL-10 (36).   
The importance of neutrophil activity and infiltrate in cancer progression and 
metastasis has become an increasingly recognised prognostic domain. Neutrophil activity has 
been shown to increase tumour progression by facilitating and encouraging angiogenesis 
(37). Neutrophil activity has also been implicated in potentiating tumour growth through the 
activation of specific inflammatory cytokines particularly IL-1 and IL-6 and via amino acid 
depletion (37) and promotes angiogenesis and the metastatic potential of cancer (37). 
Neutrophils have also been shown to direct cancer cell growth towards endothelial cells 
which can lead to increased haematological spread promoting distant metastasis (37). Indeed 
in the pre-metastatic state in patients with advanced cancer neutrophil clusters or localised 
build-ups in distant organs has been shown to be predictive of eventual metastatic spread 
(37).    
Finally, it has also been postulated that cytokines produced by the tumour/stroma 
complex can lead to marrow mesenchymal cell recruitment as a thus providing a potential 
explanation for increased marrow activation seen in the present review (35).   
However, there is recognised uptake of 18FDG by both tumour and inflammatory 
cells and that the TME consists of both tumour and inflammatory cells (38). Therefore, part 
of the glucose uptake into the tumour may be due to the infiltration of inflammatory cells.  
Indeed, Rosenberg and colleagues proposed caution when analysing PETCT scans as the 
marrow hypermetabolism shown may be due to inflammation and not necessarily where the 
tumour cells are located (39).   
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While bone marrow mesenchymal stem cells, monocyte or platelet progenitor cells are 
unregulated during the response to active malignancy an elevation of neutrophils which is 
quantitatively the most important cell type has been consistently seen in patients with active 
cancer as shown by the prognostic strength of neutrophils singularly and NLR (15,40).”   
However, confirmation of this hypothesis will require careful histological 
examination of the areas of both tumour and bone marrow increased signal uptake.”  
Irrespective, it is clear that both tumour and inflammatory cells display signs of the “Warburg 
effect” and it may be that both contribute to the increased lactate dehydrogenase and its 
prognostic value observed in patients with cancer (41,42).  
 In the present review it was confirmed that there was a relationship between tumour 
and bone marrow glucose uptake and poor outcome in patients with cancer confirming its 
clinical utility.  Given that two recent meta-analysis have established the prognostic strength 
of both singular and combined markers of the systemic inflammatory response in both 
operable and inoperable disease across multiple cancer types (15,16) it remains to be 
determined whether the prognostic value of tumour and bone marrow glucose uptake is 
determined by the systemic inflammatory response or vice versa.    
While the majority of the above studies used singular markers of the systemic 
inflammatory response these have now been surpassed by the use of composite ratios and 
cumulative scores (15,16). Furthermore in a recent study in operable colon cancer Dolan and 
co-workers showed that both composite ratios and cumulative scores had prognostic value, 
independent of TNM stage (40). However, cumulative scores, based on normal reference 
ranges, are simpler and more consistent for clinical use and should be used in future research 
to investigate the association between FDG-PET imaging and host inflammatory responses” 
 The importance of the relationship between tumour and bone marrow glucose 
uptake and the systemic inflammatory response is of more than academic interest particularly 
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in the era of immunomodulatory therapy for patients with advanced cancer.  In particular, 
modulation of the innate and adaptive immune responses will shed new light on the nature of 
this relationship (43). Furthermore, while there was some heterogeneity in the results, there 
was a relationship between tumour and bone marrow glucose uptake and poor outcomes in 
five studies including 1,525 patients. 
 
To our knowledge this is the first systematic review to examine the relationship 
between tumour glucose metabolism using PETCT imaging and host inflammatory 
responses.  From the review there appeared to be a direct relationship between the tumour 
and bone marrow glucose uptake and host systemic inflammatory responses in patients with 
common solid tumours.   Furthermore, there was a relationship between tumour and bone 




1. WHO. World Health Organization Cancer Fact Sheet. Cancer fact Sheet [01/02/2018; 
Cancer Fact Sheet Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. 
Accessed 20/03/2018, 2018. 
 
2. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting 
survival in patients with primary operable cancer. Future Oncol. 2010;6:149-163. 
 
3. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based 
prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J 
Cancer. 2011;47:2633-2641. 
 
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. 
 




6. Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC, Edwards J. Mismatch 
repair status in patients with primary operable colorectal cancer: associations with the local 
and systemic tumour environment. Br J Cancer. 2016;114:562-570. 
 
7. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J 
Cell Sci. 2012;125:5591-5596. 
 
8. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical 
regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717-727. 
 
9. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314. 
 
10. Maguire D, Neytchev O, Talwar D, McMillan D, Shiels PG. Telomere homeostasis: 
interplay with magnesium. Int J Mol Sci. 2018;19. 
 
11. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and 
metastasis. Nat Med. 2013;19:1423-1437. 
 
12. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, 
systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 
2016;263:326-336. 
 
13. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The 
systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with 
cancer. Crit Rev Oncol Hematol. 2013;88:218-230. 
 
14. McMillan DC. The systemic inflammation-based glasgow prognostic score: a decade 
of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-540. 
 
15. Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the 
systemic inflammatory response in predicting outcomes in patients with advanced inoperable 
cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134-146. 
 
16. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic 
inflammatory response in predicting outcomes in patients with operable cancer: Systematic 
review and meta-analysis. Sci Rep. 2017;7:16717. 
 
17. Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H. Preoperative 




18. Griffeth LK. Use of PET/CT scanning in cancer patients: technical and practical 
considerations. Proc (Bayl Univ Med Cent). 2005;18:321-330. 
 
19. Miele E, Spinelli GP, Tomao F, et al. Positron Emission Tomography (PET) 
radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the 
management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res. 
2008;27:52. 
 
20. Inoue K, Goto R, Okada K, Kinomura S, Fukuda H. A bone marrow F-18 FDG 
uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med. 
2009;23:643-649. 
 
21. Prevost S, Boucher L, Larivee P, Boileau R, Benard F. Bone marrow 
hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung 
cancer. J Nucl Med. 2006;47:559-565. 
 
22. Cicone F, Loose D, Deron P, et al. Prognostic value of FDG uptake by the bone 
marrow in squamous cell carcinoma of the head and neck. Nucl Med Commun. 2008;29:431-
435. 
 
23. Chang PY, Kuo YB, Wu TL, et al. Association and prognostic value of serum 
inflammation markers in patients with leukoplakia and oral cavity cancer. Clin Chem Lab 
Med. 2013;51:1291-1300. 
 
24. Chen HH, Wang HM, Fan KH, et al. Pre-treatment levels of C-reactive protein and 
squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal 
carcinoma. PLoS One. 2013;8(1). 
 
25. Jeong E, Hyun SH, Moon SH, Cho YS, Kim BT, Lee KH. Relation between tumor 
FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following 
curative resection. Medicine (Baltimore). 2017;96(5). 
 
26. Zhong L, Li C, Ren Y, Wu D. Prognostic value of (18)F-fluorodeoxyglucose PET 
parameters and inflammation in patients with nasopharyngeal carcinoma. Oncol Lett. 
2017;14:5004-5012. 
 
27. Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic Significance of FDG uptake 
of bone marrow on PET/CT in patients with non-small-cell lung cancer after curative surgical 
resection. Clin Lung Cancer. 2017;18:198-206. 
 
 20 
28. Lee JW, Seo KH, Kim ES, Lee SM. The role of (18)F-fluorodeoxyglucose uptake of 
bone marrow on PET/CT in predicting clinical outcomes in non-small cell lung cancer 
patients treated with chemoradiotherapy. Eur Radiol. 2017;27:1912-1921. 
 
29. Lee JW, Lee MS, Chung IK, Son MW, Cho YS, Lee SM. Clinical implication of FDG 
uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. World J 
Gastroenterol. 2017;23:2385-2395. 
 
30. McSorley ST, Khor BY, Tsang K, et al. The relationship between 18F FDG-PETCT 
derived markers of tumour metabolism and systemic inflammation in patients with recurrent 
disease following surgery for colorectal cancer. Colorectal Dis. 2018;20:407-415 
 
31. Lee JW, Baek MJ, Ahn TS, Lee SM. Fluorine-18-fluorodeoxyglucose uptake of bone 
marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative 
surgical resection. Eur J Gastroenterol Hepatol. 2018;30:187-194. 
 
32. van Pelt GW, Sandberg TP, Morreau H, et al. The tumour-stroma ratio in colon 
cancer: the biological role and its prognostic impact. Histopathology. 2018;73:197-206 
 
33. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated 
macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399-416. 
 
34. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector 
response to tumour and role of the microenvironment. Lancet. 2008;371:771-783. 
 
35. Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor 
progression. Front Cell Dev Biol. 2015;3. 
 
36. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time 
for reassessment. F1000Prime Rep. 2014;6. 
 
37. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. 
Nature Reviews Cancer. 2016;16:431. 
 
38. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory 
pancreatic disease. Eur J Nucl Med. 1998;25:259-264. 
 
39. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic 
response to preoperative radiochemotherapy in locally advanced rectal cancer measured by 
PET/CT. Int J Colorectal Dis. 2009;24:191-200. 
 
 21 
40. Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic 
inflammation in patients undergoing surgery for colon cancer: Comparison of composite 
ratios and cumulative scores. Br J Cancer. 2018;119:40-51. 
 
41. Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic 
index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell 
lung cancer. JAMA Oncol. 2018;4:351-357. 
 
42. Uneno Y, Taneishi K, Kanai M, et al. Development and validation of a set of six 
adaptable prognosis prediction (SAP) models based on time-series real-world big data 
analysis for patients with cancer receiving chemotherapy: A multicenter case crossover study. 
PLoS One. 2017;12:1-13. 
 
43. Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic 
antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and 




Figure1. A PRISMA Flowchart demonstrating study selection process. 
 
